Schematic illustration of PC synthesis and incorporation of labeled methyl-D9-choline via the CDP:choline and PEMT pathways (Dushianthan, Ahilanandan, et al., 2018)
1.1 Expanded indications and increasing disease prevalence In addition to type 2 diabetes and weight management as key battlegrounds today, GLP-1 therapies have shown clinical promise in treating a wider array of conditions, including Alzheimers disease, cardiovascular risk reduction , MASH (metabolic dysfunction-associated steatohepatitis) and chronic kidney disease (CKD)
Vitiligo affects roughly 0.52% of people worldwide, with onset commonly in childhood or early adulthood
Bryant, J., Baxter, L., Cave, C
PMID: 29191830 This page explains mitochondrial cocktail supplements for MELAS syndrome for educational purposes